North America Biodefense Market to 2027 - Regional Analysis and Forecasts by North America Biodefense Market to 2027 - Regional Analysis and Forecasts by Product; and Country

The North American biodefense market is estimated to reach US$ 3,357.83 Mn by 2027 from US$ 1,569.29 Mn in 2019; it is projected to grow at a CAGR of 10.1% from 2019 to 2027. The growth of the biodefense market is primarily ascribed to the presence of favorable government initiatives and increase in the number of naturally occurring outbreaks. However, the limited reach of biodefense organizations is one of the major factors restraining the growth of the market. On the other hand, increasing adoption of technologies is expected to have a positive impact on the growth of the North American biodefense market in the coming years.

Biodefense refers to the measures taken to restore biosecurity of a group of organisms that are subject to, or are likely to be subject to, biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide medical surge.

Every year, the governments of North American countries spend heavy amounts on the R&D of vaccines to stay prepared for any bioterrorism attacks. For instance, in 2018, the US government released the National Biodefense Strategy and Implementation Plan, the National Security Strategy, the National Defense Strategy, and the National Counterterrorism Strategy, and the National Counter WMD Strategy, all of which include biosecurity and biodefense. In addition, the US government is also preparing for Global Health Security Strategy and supporting the development of a 2024 framework of the Global Health Security Agenda, which involves prevention, detection, and response to natural, accidental, and intentional biological threats.

The Executive Order 13887, “Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health,” focuses on creating the National Influenza Vaccine Task Force to reform the domestic influenza vaccine enterprise in the US and also guides certain federal agencies to make specific actions toward achieving the goal. The Order provides budget of US$ 95 million that was higher than that compared to the 2020 enacted level, across Health and Human Services (HHS) for influenza vaccine manufacturing infrastructure and innovation, advanced research and development of improved vaccines, therapeutics and diagnostics, international pandemic preparedness, and improved vaccine coverage nationwide. Also, the budget covers the HHS biodefense and emergency preparedness procurement through the BioShield program and the Strategic National Stockpile. Further, it includes the budget of US$ 175 million, with a hike of US$ 50 million compared to the 2020 enacted level to support the global health security activities of the Centers For Disease Control and Prevention (CDC).

In 2004, the United States Congress passed the Project BioShield Act, calling for USD 5 billion investments for purchasing vaccines, which can be used in the event of bioterrorist attacks. This act was designed to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use. Various biosecurity-related initiatives have been planned, particularly in the matured markets, such as North America. For example, in 2017, more than 50 public and private sector biosecurity stakeholders engaged in a meeting in Johns Hopkins Center, Washington DC, for making recommendations toward the National Biodefense Strategy and Implementation Plan. As the government engages in the consolidation of current and future policies, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for bioterrorism. For instance, Spero Therapeutics, an antibiotic developer, has received US$ 15.7 million in federal research funding from Biomedical Advanced Research and Development Authority for its oral carbapenem-class candidate, SPR994. The funding was meant to be directed toward evaluating the drug's effectiveness against biological threats, including anthrax, plague, and melioidosis. In addition, Biomedical Advanced Research and Development Authority also includes provisions for up to an additional US$ 28.5 million over the next five years, and it would also support Spero's clinical development of SPR994, which is effective against complicated urinary tract infections caused by drug-resistant bacteria.

In 2019, the anthrax segment accounted for the largest market share in the North American biodefense market, based on product, that further estimated to mark the highest CAGR in the market during 2020-2027.

A few of the significant primary and secondary sources referred to while preparing this report on the biodefense market include the CDC, Food and Drug Administration (FDA), Health and Human Services (HHS), National Health Service (NHS), and Nuclear Threat Initiative (NTI).

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America biodefense market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the North America biodefense market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.